RTL1 and melanoma: In this study, we found that RTL1 activated the Wnt/β-Catenin pathway, thus suggesting that targeting RTL1 may provide a novel therapeutic target to melanoma patients or those with abnormally activated Wnt/β-Catenin signalling and related drug resistance.